Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

IMPORTANCE: Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Neurol
Auteurs principaux: Sutphen, Courtney L., Jasielec, Mateusz S., Shah, Aarti R., Macy, Elizabeth M., Xiong, Chengjie, Vlassenko, Andrei G., Benzinger, Tammie L. S., Stoops, Erik E. J., Vanderstichele, Hugo M. J., Brix, Britta, Darby, Heather D., Vandijck, Manu L. J., Ladenson, Jack H., Morris, John C., Holtzman, David M., Fagan, Anne M.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570860/
https://ncbi.nlm.nih.gov/pubmed/26147946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2015.1285
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires